Key Developments: Volcano Corp (VOLC.OQ)

VOLC.OQ on NASDAQ Stock Exchange Global Select Market

20.47USD
2 Aug 2013
Price Change (% chg)

$-0.01 (-0.05%)
Prev Close
$20.48
Open
$20.51
Day's High
$20.57
Day's Low
$20.37
Volume
15,761
Avg. Vol
238,208
52-wk High
$30.15
52-wk Low
$16.37

Search Stocks

Latest Key Developments (Source: Significant Developments)

Volcano Corp Announces Preliminary Results From ADVISE II Study
Thursday, 23 May 2013 04:30am EDT 

Volcano Corp announced preliminary results from the ADVISE (Adenosine Vasodilator Independent Stenosis Evaluation) II trial during the hot line late breaking clinical trial session at EuroPCR 2013. These prospective results confirm prior retrospective publications, and demonstrate the clinical usefulness of an iFR/Fractional Flow Reserve (FFR) Hybrid approach to simplify lesion assessment and to save the use of hyperemic drugs in a number of patients. It was also announced that this Hybrid iFR/FFR strategy, along with intravascular ultrasound (IVUS) guidance, will be used in the multi-center SYNTAX2 trial in Europe starting later this year. The ADVISE II findings replicated prior iFR retrospective publications which demonstrated that use of a Hybrid iFR/FFR workflow delivered an overall classification agreement with an FFR in more than 90% of patients participating in the trial, while saving more than 50% of such patients from hyperemic drug administration. In fact, the preliminary analysis showed 91.5% agreement with FFR and 71.5% hyperemic drug savings on a per lesion basis. Patients in ADVISE II were recruited from more than 40 centers in the United States and Europe, and all analysis was performed with operators blinded from the iFR values which were calculated offline at an independent core lab in Rotterdam, Netherlands.  Full Article

Volcano Corp Lowers FY 2013 Guidance-Conference Call
Thursday, 2 May 2013 05:00pm EDT 

Volcano Corp announced that for fiscal 2013, it expects revenues on a reported basis of $394 million to $400 million. This compares to prior guidance of $406 million to $412 million. The Company expect a net loss on a GAAP basis of $0.26 to $0.28 per share versus prior guidance for net loss of $0.19 to $0.23 per share. On a non-GAAP basis, it expect net income of $0.03 to $0.05 per diluted share. This compares to prior guidance of $0.08 to $0.11. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $408 million and EPS of $0.08 for fiscal 2013.  Full Article

Volcano Corp Lowers FY 2013 Guidance
Thursday, 21 Feb 2013 10:36pm EST 

Volcano Corp updated its fiscal 2013 guidance and expects revenues to be in the range of $406-$412 million loss on a GAAP basis of $0.19-$0.23 per share and Non-GAAP net income of $0.08-$0.11 per diluted share (EPS). According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $424 million and EPS of $0.28 for fiscal 2013.  Full Article

Volcano Corp Issues FY 2013 Guidance
Thursday, 21 Feb 2013 04:06pm EST 

Volcano Corp announced that for fiscal 2013, it expects revenues will be in the range of $422.0-$428.0 million, net loss on a GAAP basis of $0.10-$0.14 per share in 2013 and non-GAAP net income of $0.16-$0.20 per diluted share in 2013.  Full Article

Volcano Corp Issues Q4 2012 Revenue Guidance In Line With Analysts' Estimates; Updates On FY 2012 Revenue Guidance
Monday, 7 Jan 2013 04:05pm EST 

Volcano Corp announced that for the fourth quarter of 2012, it expects total revenues to be approximately $102.5 million, bringing fiscal 2012 revenues to approximately $381.9 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $102 million for the fourth quarter of 2012; revenue of $382 million for fiscal 2012.  Full Article

Volcano Corp Prices Offering Of $400 Million 1.75% Convertible Senior Notes Due 2017
Wednesday, 5 Dec 2012 07:30am EST 

Volcano Corp announced the pricing of its public offering of $400 million aggregate principal amount of 1.75% convertible senior notes due December 1, 2017 registered under the Securities Act of 1933, as amended. Prior to August 7, 2017, the notes will be convertible only upon certain circumstances and during certain periods. The offering is expected to close on December 10, 2012. The notes will mature on December 1, 2017. The notes will be general senior unsecured obligations of Volcano, and interest will be payable semi-annually in cash at a rate of 1.75% per annum on June 1 and December 1 of each year, beginning June 1, 2013. Volcano estimates that net proceeds from the offering will be approximately $387.1 million, after deductions. Volcano expects to use approximately $31.4 million of the net proceeds from the sale of the notes to pay the cost of the convertible note hedge transactions described below (after such cost is partially offset by the proceeds that Volcano expects to receive from the warrant transactions described below) and may use up to $105 million of the net proceeds from the offering to fund repurchases of up to $90 million of its outstanding 2.875% Convertible Senior Notes due 2015. Volcano may also use a portion of the net proceeds to invest in or acquire complementary products, businesses or technologies. The remaining net proceeds are intended for working capital and general corporate purposes.  Full Article

Volcano Corp Announces $350 Million Convertible Senior Notes Due 2017
Monday, 3 Dec 2012 04:42pm EST 

Volcano Corp announced that $350 million principal amount of convertible senior notes due December 1, 2017 in an offering registered under the Securities Act of 1933, as amended. Prior to August 7, 2017, the notes will be convertible only upon certain circumstances and during certain periods. Upon conversion, holders will receive up to the principal amount of the notes in cash and any excess conversion value in shares of Volcano's common stock. Volcano also expects to grant the underwriters of the offering an option to purchase up to $52.5 million aggregate principal amount of additional notes to cover over-allotments. The notes will be general senior unsecured obligations of Volcano and will pay interest semi-annually. The interest rate, conversion rate, offering price and other terms will be determined at the time of pricing of the offering. Volcano expects to use a portion of the net proceeds of the offering of the notes to pay the costs of the convertible note hedge transactions described below, taking into account the proceeds of the warrant transactions described below, and may use up to approximately $50.0 million of the net proceeds from the offering to fund repurchases of its outstanding 2.875% Convertible Senior Notes due 2015 (the "2015 Notes"). Volcano may also use a portion of the net proceeds to invest in or acquire complementary products, businesses or technologies. The remaining net proceeds are intended for working capital and general corporate purposes.  Full Article

Volcano Corp Announces Agreement To Acquire Crux Biomedical
Monday, 3 Dec 2012 08:13am EST 

Volcano Corp announced that it has signed an agreement to acquire Crux Biomedical, a privately-held company that has developed a differentiated inferior vena cava (IVC) filter-the Crux VCF System-to treat pulmonary embolisms (PE's). Under terms of the agreement, Volcano will pay $36.0 million in cash at closing, which is expected to occur within in the second week of December 2012. Under terms of the agreement, Volcano will pay $36.0 million in cash at closing. Volcano will also pay up to approximately $3.1 million in Crux transaction expenses. The merger agreement also provides for a potential post-closing cash milestone payment of $3.0 million upon FDA clearance of a 510(k) application submitted by Volcano on or before June 30, 2013, for a retrieval device currently being developed by Crux. In addition, Volcano may make additional cash payments for up to four years, based on sales of Crux products following their commercial launch.  Full Article

Volcano Corp Signs Agreement to Acquire Sync-Rx Ltd.
Friday, 23 Nov 2012 08:00am EST 

Volcano Corp announced that it has entered into a definitive agreement to acquire Sync-Rx Ltd., a privately-held company based in Israel that develops advanced software applications that optimize and facilitate transcatheter cardiovascular interventions using automated online image processing. It is anticipated the transaction will close within the next 30 days. Sync-Rx, Ltd. develops software that optimizes and facilitates transcatheter cardiovascular interventions using automated online image processing. The company's current focus is on coronary catheterizations. Sync-Rx, Ltd. is located in Netanya, Israel.  Full Article

Volcano Corp Lowers FY 2012 Revenue Guidance; Reaffirms FY 2012 EPS Guidance
Tuesday, 6 Nov 2012 04:05pm EST 

Volcano Corp announced that for fiscal 2012, it expects total revenues for 2012 will be in the range of $380-$384 million and earnings per diluted share of $0.18-$0.21. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $386 million and EPS of $0.20 for fiscal 2012.  Full Article

Search Stocks